½ÃÀ庸°í¼­
»óǰÄÚµå
1381777

¼¼°èÀÇ ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : ±â¼úº°, ¿ëµµº°, Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Nanotechnology Drug Delivery Market Size study & Forecast, by Technology by Application and Regional Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

³ª³ëÅ×Å©³î·¯Áö ÀǾàǰÀº ½ÅüÀÇ Æ¯Á¤ ¼¼Æ÷, Á¶Á÷ ¹× ±â°ü¿¡ ¾à¹°À» Ç¥ÀûÈ­ÇÏ¿© Àü´ÞÀ» °­È­ÇÕ´Ï´Ù.

¿©±â¿¡´Â Á¦¾îµÈ ¹æ½ÄÀ¸·Î Ä¡·áÁ¦¸¦ Àü´ÞÇϱâ À§ÇÑ ³ª³ë ÀÔÀÚ ¶Ç´Â ³ª³ë ½ºÄÉÀÏ Àç·áÀÇ ¼³°è, °³¹ß ¹× Ȱ¿ëÀÌ Æ÷ÇԵ˴ϴÙ. ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´ÞÀº ¾à¹° Ä¡·áÀÇ È¿°ú¿Í ¾ÈÀü¼ºÀ» Çâ»ó½ÃÅ´À¸·Î½á ÀÇ·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Â ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ¿¬±¸ °³¹ßÀÌ È°¹ßÇÑ ºÐ¾ß·Î, ¾Ï, ½ÉÇ÷°ü Áúȯ, ½Å°æ ÅðÇ༺ Áúȯ, °¨¿°¼º Áúȯ µî ´Ù¾çÇÑ Áúȯ¿¡ ´ëÇÑ ¼ö¸¹Àº ³ª³ëÅ×Å©³î·¯Áö ±â¹Ý ¾à¹°Àü´Þ ½Ã½ºÅÛÀÌ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ´Â ¹è°æ¿¡´Â ¾Ï, À¯Àü¼º Áúȯ, ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ±×¸®°í Àü ¼¼°èÀûÀ¸·Î ÀǾàǰ °³¹ß Ȱµ¿ÀÌ È°¹ßÇÏ°Ô ÁøÇàµÇ°í ÀÖ´Â Á¡ µîÀÌ ÀÖ½À´Ï´Ù.

´ç´¢º´, ½ÉÇ÷°ü Áúȯ, ¾Ï µî ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡¸¦ ÁÖ¿ä ¿äÀÎÀ¸·Î ´Ù¾çÇÑ ¸¸¼ºÁúȯ¿¡ ´ëÇÑ Ç¥Àû Àü´Þ ½Å¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´ç´¢º´Àº Àü ¼¼°èÀûÀ¸·Î Á¡Á¡ ´õ ÈçÇØÁö°í ÀÖ½À´Ï´Ù. ±¹Á¦´ç´¢º´¿¬¸Í(IDF)ÀÇ Diabetes Atlas Tenth Edition 2021¿¡ µû¸£¸é, 2021³â¿¡´Â 5¾ï 3,700¸¸ ¸í(20-79¼¼)ÀÌ ´ç´¢º´À» ¾Î°í ÀÖ´Â °ÍÀ¸·Î Ãß»êµË´Ï´Ù. ÀÌ ÀÚ·á¿¡ µû¸£¸é, 2030³â¿¡´Â Àü ¼¼°è 6¾ï 4,300¸¸ ¸íÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, 2045³â¿¡´Â 7¾ï 8,300¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ç´¢º´ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Ä¡·á¿Í Áø´ÜÀ» À§ÇÑ º¸´Ù ±â¼úÀûÀ¸·Î Á¤±³ÇÑ ¾à¹°Àü´Þ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÒ °ÍÀº ºÐ¸íÇÕ´Ï´Ù. ¶ÇÇÑ, Globocan(Global Cancer Observatory)ÀÇ Statistics 2020¿¡ µû¸£¸é, 2020³â¿¡´Â Àü ¼¼°èÀûÀ¸·Î 1,930¸¸ ¸íÀÇ ¾Ï ȯÀÚ°¡ »õ·Î ¹ß»ýÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ÀÚ·á´Â ¾ÏÀÌ Àü ¼¼°èÀûÀ¸·Î ±ÞÁõÇϰí ÀÖÀ½À» ÁöÀûÇϸç, 2040³â±îÁö ³²³à¸¦ ¸··ÐÇϰí 2,880¸¸ ¸íÀÌ »õ·Ó°Ô ¾Ï¿¡ °É¸± °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. °á°úÀûÀ¸·Î ¸¸¼º ÁúȯÀÇ ¹ßº´·ü Áõ°¡´Â ³ª³ëÅ×Å©³î·¯Áö ±â¹ÝÀÇ ¾à¹°Àü´Þ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÀÚ±ØÇÏ¿© ½ÃÀå È®´ë¸¦ ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ¶ÇÇÑ, ½ÃÀå È®´ë´Â ³ª³ëÅ×Å©³î·¯Áö °³¹ß ¹× R&D ³ë·ÂÀÇ Áõ°¡·Î ÀÎÇØ Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 7¿ù EUÀÇ Horizon 2020 B-SMART ÇÁ·ÎÁ§Æ®´Â Ç÷¾×-³úô¼ö¾× À庮À» Åë°úÇÏ¿© RNA¸¦ Àü´ÞÇÒ ¼ö ÀÖ´Â µ¶ÀÚÀûÀÎ ±â¼úÀ» °³¹ßÇÏ¿© ³ú¿¡ Á÷Á¢ Ä¡·áÁ¦¸¦ Åõ¿©ÇÒ ¼ö ÀÖµµ·Ï ÇÏ·Á°í ÇÕ´Ï´Ù. µû¶ó¼­ ³ª³ë ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ ½ÅÈï±¹ ½ÃÀå °³Ã´ÀÌ ½ÃÀå È®´ëÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ª³ëÅ×Å©³î·¯ÁöÀÇ ½ÅÈï±¹ ½ÃÀåÀÇ ¹ßÀü°ú ¿¬±¸°³¹ß Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ½ÃÀå¿¡ »õ·Î¿î ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ±â¼úÀÇ ³ôÀº ºñ¿ë°ú »ó¾÷Àû µµÀÔ¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦´Â 2023-2030³â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¼¼°è ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ´Ù¾çÇÑ ÁúȯÀÇ À¯º´·ü Áõ°¡, ÁÖ¿ä ½ÃÀå ÁøÀÔ ±â¾÷ÀÇ Á¸Àç, R&D Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ÀÌ Áö¿ªÀÇ ÀÓ»ó½ÃÇè ¹× ½Å¾à °³¹ß Ȱµ¿ Áõ°¡, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ 2022³â ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù.

ÀÌ Á¶»çÀÇ ¸ñÀûÀº ÃÖ±Ù ¸î ³â°£ ´Ù¾çÇÑ ºÎ¹®°ú ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ ÆÄ¾ÇÇϰí ÇâÈÄ ¸î ³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼­´Â Á¶»ç ´ë»ó ±¹°¡ÀÇ »ê¾÷ÀÇ ÁúÀû, ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀΰú °úÁ¦¿Í °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸µµ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ±â¾÷ÀÇ °æÀï »óȲ°ú ±â¼ú Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¸¶ÀÌÅ©·Î ½ÃÀåÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¼¼°è ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • »ê¾÷ÀÇ ÁøÈ­
    • Á¶»ç ¹üÀ§
  • Á¶»ç ´ë»ó ¿¬µµ
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¼¼°è ½ÃÀå ¿ªÇÐ

  • ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀåÀÇ ¿µÇ⠺м®(2020-2030³â)
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
      • ¾Ï, À¯Àü¼º Áúȯ, ½ÉÇ÷°üÁúȯ À¯º´·ü Áõ°¡
      • °³º°È­ ÀǾàǰ¿¡ ´ëÇÑ ±âÈ£ »ó½Â
      • ¼¼°èÀÇ ÀǾàǰ °³¹ß Ȱµ¿ Áõ°¡
    • ½ÃÀå °úÁ¦
      • ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ±â¼úÀÇ °íºñ¿ë
      • Á¦Ç°È­¸¦ À§ÇÑ ¾ö°ÝÇÑ ±ÔÁ¦
    • ½ÃÀå ±âȸ
      • ³ª³ë ½ºÄÉÀÏ ±â¼ú ¹ßÀü
      • ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡

Á¦4Àå ¼¼°èÀÇ ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's 5 Force ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è
  • Porter's 5 Force ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19 ¿µÇ⠺м®
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ °üÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð°ú Á¦¾È

Á¦5Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¼¼°è ½ÃÀå : ±â¼úº°

  • ½ÃÀå ÇöȲ
  • ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¼¼°è ½ÃÀå : ±â¼úº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¼¼°è ½ÃÀå : ±â¼úº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ³ª³ë°áÁ¤
    • ³ª³ëÀÔÀÚ
    • ¸®Æ÷¼Ø
    • ¹Ì¼¿
    • ±âŸ

Á¦6Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¼¼°è ½ÃÀå : ¿ëµµº°

  • ½ÃÀå ÇöȲ
  • ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¼¼°è ½ÃÀå : ¿ëµµº°, ½ÇÀû - ÀáÀ缺 ºÐ¼®
  • ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¼¼°è ½ÃÀå : ¿ëµµº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ½Å°æÇÐ
    • Á¾¾çÇÐ
    • ½ÉÇ÷°ü/»ý¸®ÇÐ
    • Ç׿°Áõ/¸é¿ªÇÐ
    • Ç×°¨¿°Áõ
    • ±âŸ ¿ëµµ

Á¦7Àå ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ¼¼°è ½ÃÀå, Áö¿ª ºÐ¼®

  • ÁÖ¿ä ±¹°¡
  • ÁÖ¿ä ½ÅÈï ±¹°¡
  • ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå, Áö¿ªº° ½ÃÀå ÇöȲ
  • ºÏ¹Ì
    • ¹Ì±¹
      • ±â¼úº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ¿ëµµº°, ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
    • ij³ª´Ù
  • À¯·´ÀÇ ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå ÇöȲ
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå ÇöȲ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ³ª³ëÅ×Å©³î·¯Áö ¾à¹°Àü´Þ ½ÃÀå ÇöȲ
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • AbbVie Inc
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ °¡¿ë¼º¿¡ µû¶ó ´Ù¸§)
      • Á¦Ç° °³¿ä
    • Aquanova AG
    • BlueWillow Biologics
    • Bristol Myers Squibb(Celgene Inc)
    • Cytimmune Sciences Inc
    • NanoCarrier Co Ltd
    • NanOlogy LLC
    • Taiwan Liposome Co
    • Merck KGaA
    • Aphios Corporation

Á¦9Àå Á¶»ç °úÁ¤

  • Á¶»ç °úÁ¤
    • µ¥ÀÌÅÍ ±¤¾÷
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
  • Á¶»ç °¡Á¤
ksm 23.11.28

Nanotechnology drugs enhance the targeted delivery of drugs to specific cells, tissues, or organs in the body. It involves the design, development, and utilization of nanoparticles or nanoscale materials to deliver therapeutic agents in a controlled manner. Nanotechnology drug delivery has the potential to revolutionize healthcare by improving the efficacy and safety of drug treatments. It is an active area of research and development, with numerous nanotechnology-based drug delivery systems being investigated for various diseases, including cancer, cardiovascular disorders, neurodegenerative diseases, and infectious diseases. The Nanotechnology Drug Delivery market is expanding because of factors such as the growing prevalence of cancer and genetic and cardiovascular diseases and growing preference for personalized medicines as well as the rising number of drug development activities across the world.

Demand for novel drugs with targeted delivery for various chronic diseases has increased primarily due to the rising prevalence of chronic diseases such as diabetes, cardiovascular, cancer disease. Diabetes is becoming more and more common among people worldwide. According to information from the International Diabetes Federation (IDF) Diabetes Atlas Tenth Edition 2021, 537 million persons (aged 20 to 79) were estimated to have diabetes in 2021. According to the same source, by 2030 there will be 643 million individuals worldwide living with diabetes, and by 2045 there will be 783 million. The demand for more technologically sophisticated drug delivery alternatives for treatment and diagnosis will undoubtedly rise as the prevalence of diabetes rises. In addition, the Global Cancer Observatory's (Globocan) Statistics 2020 report that there were 19.3 million new cases of cancer worldwide in 2020,. The same source notes that cancer is becoming more common worldwide and predicts that by 2040, there would be 28.8 million new instances of cancer in people of both sexes. As a result, the growing incidence of chronic diseases stimulates the demand for drug delivery systems based on nanotechnology, promoting market expansion. Furthermore, the expansion of the market has also been assisted by growing developments in nanoscale technologies and research & development efforts. In July 2022, for instance, the EU Horizon 2020 B-SMART project tried to develop a unique technique for delivering RNA past the blood-cerebrospinal fluid barrier, enabling therapies to be given directly to the brain. Therefore, developments in nano drug delivery systems fuel market expansion. Moreover, increasing advancements in nanoscale technologies, and a rising number of investments in research and development activities is creating new opportunities for the market. However, the high cost of nanotechnology drug delivery techniques and stringent regulations for commercial introduction stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Nanotechnology Drug Delivery Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to rising prevalence of various diseases, the presence of key market players, rising number of investments in research and development activities, rising number of clinical trials and drug discoveries activities in the region as well as rising demand for personalized medicine in the region.

Major market players included in this report are:

  • AbbVie Inc
  • Aquanova AG
  • BlueWillow Biologics
  • Bristol Myers Squibb (Celgene Inc)
  • Cytimmune Sciences Inc
  • NanoCarrier Co Ltd
  • NanOlogy LLC
  • Taiwan Liposome Co
  • Merck KGaA
  • Aphios Corporation

Recent Developments in the Market:

  • In June 2022, Researchers at the Baker Heart and Diabetes Institute created and developed a novel nanoparticle drug delivery system that can diagnose and treat several ailments as well as significantly increase the efficacy of a medication used to treat atherosclerosis.
  • In January 2022, Researchers at Case Western Reserve University developed nanoparticles that deliver clot-promoting enzymes to the bleeding site and then release them there to produce fibrin, the body's meshlike component that is essential for stopping the bleeding, where it is needed.

Global Nanotechnology Drug Delivery Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Technology, Application, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Technology offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Technology:

  • Nanocrystals
  • Nanoparticles
  • Liposomes
  • Micelles
  • Others

By Application:

  • Neurology
  • Oncology
  • Cardiovascular/Physiology
  • Anti-inflammatory/Immunology
  • Anti-infective
  • Other Applications

By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • ROE
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Nanotechnology Drug Delivery Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Nanotechnology Drug Delivery Market, by Technology, 2020-2030 (USD Billion)
    • 1.2.3. Nanotechnology Drug Delivery Market, by Application, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Nanotechnology Drug Delivery Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Nanotechnology Drug Delivery Market Dynamics

  • 3.1. Nanotechnology Drug Delivery Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Growing prevalence of cancer and genetic and cardiovascular diseases
      • 3.1.1.2. Growing preference for personalized medicines
      • 3.1.1.3. Rising number of drug development activities across the world.
    • 3.1.2. Market Challenges
      • 3.1.2.1. High cost of nanotechnology drug delivery technique
      • 3.1.2.2. Stringent regulations for commercialization of product
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing developments in nanoscale technologies
      • 3.1.3.2. Rising investments for research and development

Chapter 4. Global Nanotechnology Drug Delivery Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Nanotechnology Drug Delivery Market, by Technology

  • 5.1. Market Snapshot
  • 5.2. Global Nanotechnology Drug Delivery Market by Technology, Performance - Potential Analysis
  • 5.3. Global Nanotechnology Drug Delivery Market Estimates & Forecasts by Technology 2020-2030 (USD Billion)
  • 5.4. Nanotechnology Drug Delivery Market, Sub Segment Analysis
    • 5.4.1. Nanocrystals
    • 5.4.2. Nanoparticles
    • 5.4.3. Liposomes
    • 5.4.4. Micelles
    • 5.4.5. Others

Chapter 6. Global Nanotechnology Drug Delivery Market, by Application

  • 6.1. Market Snapshot
  • 6.2. Global Nanotechnology Drug Delivery Market by Application, Performance - Potential Analysis
  • 6.3. Global Nanotechnology Drug Delivery Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
  • 6.4. Nanotechnology Drug Delivery Market, Sub Segment Analysis
    • 6.4.1. Neurology
    • 6.4.2. Oncology
    • 6.4.3. Cardiovascular/Physiology
    • 6.4.4. Anti-inflammatory/Immunology
    • 6.4.5. Anti-infective
    • 6.4.6. Other Applications

Chapter 7. Global Nanotechnology Drug Delivery Market, Regional Analysis

  • 7.1. Top Leading Countries
  • 7.2. Top Emerging Countries
  • 7.3. Nanotechnology Drug Delivery Market, Regional Market Snapshot
  • 7.4. North America Nanotechnology Drug Delivery Market
    • 7.4.1. U.S. Nanotechnology Drug Delivery Market
      • 7.4.1.1. Technology breakdown estimates & forecasts, 2020-2030
      • 7.4.1.2. Application breakdown estimates & forecasts, 2020-2030
    • 7.4.2. Canada Nanotechnology Drug Delivery Market
  • 7.5. Europe Nanotechnology Drug Delivery Market Snapshot
    • 7.5.1. U.K. Nanotechnology Drug Delivery Market
    • 7.5.2. Germany Nanotechnology Drug Delivery Market
    • 7.5.3. France Nanotechnology Drug Delivery Market
    • 7.5.4. Spain Nanotechnology Drug Delivery Market
    • 7.5.5. Italy Nanotechnology Drug Delivery Market
    • 7.5.6. Rest of Europe Nanotechnology Drug Delivery Market
  • 7.6. Asia-Pacific Nanotechnology Drug Delivery Market Snapshot
    • 7.6.1. China Nanotechnology Drug Delivery Market
    • 7.6.2. India Nanotechnology Drug Delivery Market
    • 7.6.3. Japan Nanotechnology Drug Delivery Market
    • 7.6.4. Australia Nanotechnology Drug Delivery Market
    • 7.6.5. South Korea Nanotechnology Drug Delivery Market
    • 7.6.6. Rest of Asia Pacific Nanotechnology Drug Delivery Market
  • 7.7. Latin America Nanotechnology Drug Delivery Market Snapshot
    • 7.7.1. Brazil Nanotechnology Drug Delivery Market
    • 7.7.2. Mexico Nanotechnology Drug Delivery Market
  • 7.8. Middle East & Africa Nanotechnology Drug Delivery Market
    • 7.8.1. Saudi Arabia Nanotechnology Drug Delivery Market
    • 7.8.2. South Africa Nanotechnology Drug Delivery Market
    • 7.8.3. Rest of Middle East & Africa Nanotechnology Drug Delivery Market

Chapter 8. Competitive Intelligence

  • 8.1. Key Company SWOT Analysis
    • 8.1.1. Company 1
    • 8.1.2. Company 2
    • 8.1.3. Company 3
  • 8.2. Top Market Strategies
  • 8.3. Company Profiles
    • 8.3.1. AbbVie Inc
      • 8.3.1.1. Key Information
      • 8.3.1.2. Overview
      • 8.3.1.3. Financial (Subject to Data Availability)
      • 8.3.1.4. Product Summary
      • 8.3.1.5. Recent Developments
    • 8.3.2. Aquanova AG
    • 8.3.3. BlueWillow Biologics
    • 8.3.4. Bristol Myers Squibb (Celgene Inc)
    • 8.3.5. Cytimmune Sciences Inc
    • 8.3.6. NanoCarrier Co Ltd
    • 8.3.7. NanOlogy LLC
    • 8.3.8. Taiwan Liposome Co
    • 8.3.9. Merck KGaA
    • 8.3.10. Aphios Corporation

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦